Magprol CR 200 Tablet contains Magnesium Valproate 200mg, an anticonvulsant and mood-stabilizing agent primarily indicated for the management of epilepsy and bipolar disorder. Magnesium Valproate acts by increasing gamma-aminobutyric acid (GABA) levels in the brain, thereby exerting an inhibitory effect on neuronal excitability and preventing seizure activity. The controlled-release formulation of Magprol CR 200 ensures a sustained therapeutic plasma concentration, enhancing compliance and minimizing fluctuations in drug levels. This medication is effective in controlling various types of seizures, including generalized tonic-clonic, absence, and complex partial seizures, and is also utilized in the prophylaxis of manic episodes in bipolar disorder. Magprol CR 200 should be administered under medical supervision with dosage adjustments tailored to individual patient response and tolerability. Common adverse effects may include gastrointestinal disturbances, dizziness, tremor, and weight gain, while serious side effects such as hepatotoxicity and pancreatitis, though rare, require immediate medical attention. Regular monitoring of liver function tests, blood counts, and serum drug levels is recommended during therapy. Magprol CR 200 is contraindicated in patients with known hypersensitivity to valproate compounds, severe hepatic impairment, and mitochondrial disorders. Caution is advised during pregnancy due to potential teratogenic effects.